Ionis announces proposed public offering of common stock

Core Viewpoint - Ionis Pharmaceuticals, Inc. announced a proposed underwritten public offering of $500 million of its common stock, with an option for underwriters to purchase an additional $75 million [1] Group 1: Offering Details - The net proceeds from the offering will be used to fund independent commercial launches, late-stage clinical programs, earlier pipeline programs, research and development activities, as well as for working capital and general corporate purposes [1] - The offering is subject to market and other conditions, with no assurance on the completion, size, or terms of the offering [1] - Morgan Stanley and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering [2] Group 2: Regulatory Information - A shelf registration statement for the offered securities was filed with the SEC on November 24, 2023, and became effective upon filing [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC on September 9, 2024, and will be available for free on the SEC's website [3] Group 3: Company Background - Ionis Pharmaceuticals has been innovating medicines for serious diseases for three decades, currently marketing five medicines and maintaining a leading pipeline in neurology, cardiology, and other high-need areas [5] - The company is a pioneer in RNA-targeted medicines and continues to drive innovation in RNA therapies and gene editing [5]